No Data
No Data
A. G. P. Maintains Can-Fite BioPharma(CANF.US) With Buy Rating, Cuts Target Price to $4.5
Express News | Can Fite Biopharma Ltd : Alliance Global Partners Cuts Target Price to $4.5 From $12
Express News | D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $10 Price Target
Can-Fite BioPharma Reports 2024 Financial Results and Clinical Progress
Can-Fite Announces $3.0 Million Registered Direct Offering of American Depositary Shares
Can-Fite BioPharma Trading Halted, News Pending
Thomas369 : yup